Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Payables (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Payables data on record, last reported at $1.2 million in Q4 2025.

  • For Q4 2025, Payables fell 26.17% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 26.17%, while the annual FY2025 figure was $1.2 million, 26.17% down from the prior year.
  • Payables reached $1.2 million in Q4 2025 per TNGX's latest filing, down from $2.2 million in the prior quarter.
  • Across five years, Payables topped out at $6.3 million in Q3 2022 and bottomed at $26279.0 in Q2 2021.
  • Average Payables over 5 years is $2.9 million, with a median of $3.0 million recorded in 2021.
  • Peak YoY movement for Payables: surged 60093.61% in 2021, then tumbled 77.84% in 2024.
  • A 5-year view of Payables shows it stood at $3.2 million in 2021, then surged by 38.03% to $4.5 million in 2022, then crashed by 37.46% to $2.8 million in 2023, then crashed by 42.51% to $1.6 million in 2024, then fell by 26.17% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $1.2 million in Q4 2025, $2.2 million in Q3 2025, and $2.6 million in Q2 2025.